English
Back
Download
Log in to access Online Inquiry
Back to the Top
avatar
Jaguar8 commented on a stock · Nov 12, 2024 19:01

NEWS

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
Lipella Pharmaceuticals (Nasdaq: LIPO) announced the issuance of U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform. The patent, titled 'Delivery of Agents Using Metastable Liposomes,' extends market exclusivity for the company's lead clinical assets, LP-10and LP-310, currently in Phase 2 trials. LP-10 is a liposomal formulation of tacrolimus for hemorrhagic cystitis, while LP-310 is an oral rinse for oral lichen planus. The company holds additional patents in the United States, Australia, and Canada, providing exclusivity until 2035.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
Translate
Report
6209 Views
Comment
Sign in to post a comment
    avatar
    Jaguar8
    Spread kindness and love. Life is short. Don’t let greed eat you.
    9346
    Followers
    56
    Following
    112K
    Visitors
    Follow
    Heat List
    US
    SymbolMini ChartPrice
    TSLA
    Tesla
    -- 248.710
    NVDA
    NVIDIA
    -- 117.700
    PLTR
    Palantir
    -- 90.960
    MSTR
    Strategy
    -- 304.000
    AAPL
    Apple
    -- 218.270
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.